29
November 2024
Argent BioPharma
Ltd.
(Argent BioPharma or the Company)
ASX Delisting
Update
and
Notice of Intention to Delist
from the London Stock Exchange
Argent BioPharma, an innovative
multidisciplinary drug discovery company within the
biopharmaceutical sector, wishes to advise, that following a
detailed review of both the listing requirements and costs
associated with the transfer of all its ordinary shares, from the
equity shares (international commercial companies secondary
listing) category of the Official List maintained by the Financial
Conduct Authority ("FCA")
("Official List"), to the
equity shares (commercial companies) ("ESCC") category of the Official List,
the Company has decided to retain its listing on the Australian
Securities Exchange ("ASX")
and apply to the FCA and the London Stock Exchange ("LSE") to cancel the admission of
Argent BioPharma's shares to listing in the International
Commercial Companies Secondary Listing category of the Official
List of the FCA and trading under the ticker "RGT" on the Main
Market for listed securities of the LSE.
The Company hereby gives notice
that, in an effort to streamline and simplify processes and
increase administrative efficiencies, it will requested that (i)
the FCA cancel the listing of the Company's ordinary shares of NPV
("Shares") on the equity
shares international commercial companies secondary listing segment
of the Official List of the FCA, and (ii) the LSE cancel the
admission to trading of the Company's Shares on the main market for
listed securities of the LSE (collectively, the "Delisting").
In accordance with UK Listing Rule
21.2.17, Argent BioPharma is required to give at least 20 business
days' notice of the intended Delisting. It is expected the
Delisting will become effective from 08:00 (GMT) on 31 December
2024. The last day of trading of Argent BioPharma shares on the LSE
will be Monday, 31 December 2024.
As the Company is assigned to the
equity shares international commercial companies secondary listing
segment of the Official List, no shareholder approval is required
for the Delisting. Following the Delisting, (i) it will no
longer be possible to trade Shares on the LSE, and (ii) the Company
will maintain its listings on the ASX and
OTCQB Venture Market.
Any shareholder with questions
regarding the Delisting is encouraged to consult their investment
adviser or broker. The Company will provide an update to holders of
its Depositary Interests, outlining how their holdings will be
affected and the steps required to ensure the future tradability of
their securities.
The Company's main operations and
management are based in the EU, with a growing investor base in the
United States of America. Looking ahead, Argent BioPharma may still
look to explore opportunities to expand its accessibility to
investors, including the potential for a dual listing on a United
States based exchange.
-Ends-
Authorised for release by the board of directors, for further
information please contact:
About Argent BioPharma
Argent BioPharma Limited (the
"Company") (ASX: RGT; LSE:
RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development
Company within the biopharmaceutical sector. The Company
focuses on multidisciplinary methods with Nanotechnology,
developing multi-target therapies for comprehensive disease
management, especially concerning the central nervous system
("CNS") and Immunology treatments.
Follow us through our social media
channels:
LinkedIn: Argent
BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent
BioPharma